Copper-binding peptides: GHK-Cu, AHK-Cu, and the evidence map

The GHK-Cu literature spans biochemical work, cultured-cell experiments, animal models, gene-expression analyses, and some human or cosmetic contexts. Reviews can map this breadth, but individual claims still need the underlying primary source. Results from wound models, cultured fibroblasts, or gene-expression datasets answer different questions.

When a source reports changes in collagen-related markers, inflammatory signals, or tissue appearance, preserve the model and endpoint. Do not translate a molecular or localized observation into a guarantee of systemic repair, rejuvenation, hair growth, or treatment of disease.

AHK-Cu has been studied in a smaller and more specialized literature, including experimental work involving dermal papilla cells and hair-related biology. That scope is narrower than the broad claims often attached to 'copper peptides' as one category. The sequence and experimental endpoint must be named before comparing it with GHK-Cu.

A cell-culture finding can support a hypothesis about signaling or proliferation in that system. It cannot establish a clinically meaningful hair or skin outcome without appropriate controlled human evidence.

Ask five questions: which peptide sequence, which copper complex, which formulation or route, which model or population, and which measured outcome? Then identify whether the evidence is primary, replicated, controlled, and human. Product-level claims require evidence for the actual product, not merely a paper about a related complex.

This overview does not provide formulation, concentration, reconstitution, injection, topical-use, or sourcing instructions. It is a map for reading research and keeping molecular identity attached to the evidence.